<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26703">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01859715</url>
  </required_header>
  <id_info>
    <org_study_id>11-1692</org_study_id>
    <nct_id>NCT01859715</nct_id>
  </id_info>
  <brief_title>Emergency Department (ED) Drug Interaction in Emergency Department Patients</brief_title>
  <official_title>Hepatic Cytochrome Drug Interactions in Emergency Department Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines how hepatic cytochrome CYP2D6 drug interactions affects the efficacy of
      oxycodone, hydrocodone, and ondansetron in Emergency Department (ED) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with pain and/or nausea are enrolled in the Emergency Department (ED). They are
      given either oxycodone, hydrocodone, or ondansetron at the discretion of the Emergency
      Department (ED) provider or the triage nurse by triage protocol. Detailed prescription, over
      the counter, herbal, supplement, and illicit drug ingestion histories are taken from the
      patient or their health care proxy. Serial visual analogue scales are captured prior to
      study drug administration then between 30 and 90 minutes following drug administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>difference in clinically significant visual analogue scale (VAS) change between CYP2D6 users and non-users</measure>
    <time_frame>90 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinically significant visual analogue scale (VAS) oxycodone, hydrocodone, or ondansetron. Clinically significant change defined as 13 mm change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse drug events</measure>
    <time_frame>Duration of ED stay, &lt;24 hours. (up to 24 hours)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine if there is a difference in ADEs between groups with and without CYP2D6 drug interactions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Drug Interactions</condition>
  <arm_group>
    <arm_group_label>Opioid treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nausea-observational group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients given ondansetron by ED provider decision or by triage nurse. This is an observational cohort only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization.</description>
    <arm_group_label>Opioid treatment group</arm_group_label>
    <arm_group_label>Nausea-observational group</arm_group_label>
    <other_name>Oxycodone, oxycontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodone</intervention_name>
    <description>Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization.</description>
    <arm_group_label>Opioid treatment group</arm_group_label>
    <arm_group_label>Nausea-observational group</arm_group_label>
    <other_name>Vicodin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Subjects given ondansetron for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.</description>
    <arm_group_label>Nausea-observational group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  self-reported pain or nausea identified by the initial nursing assessment

        Exclusion Criteria:

          -  unable to speak English,

          -  &lt; 18 y.o.,

          -  previously diagnosed with chronic pain or cyclic vomiting
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew A Monte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 21, 2013</lastchanged_date>
  <firstreceived_date>May 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug drug interaction</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>opioid efficacy</keyword>
  <keyword>pain</keyword>
  <keyword>nausea</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
